Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease

Dick de Zeeuw; Tadao Akizawa; Paul Audhya; George L Bakris; Melanie Chin; Heidi Christ-Schmidt; Angie Goldsberry; Mark Houser; Melissa Krauth; Hiddo J Lambers Heerspink; John J McMurray; Colin J Meyer; Hans-Henrik Parving; Giuseppe Remuzzi; Robert D Toto; Nosratola D Vaziri; Christoph Wanner; Janet Wittes; Danielle Wrolstad; Glenn M Chertow; BEACON Trial Investigators

doi:10.1056/NEJMoa1306033

Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease

Dick de Zeeuw, Tadao Akizawa, Paul Audhya, George L Bakris, Melanie Chin, Heidi Christ-Schmidt, Angie Goldsberry, Mark Houser, Melissa Krauth, Hiddo J Lambers Heerspink, John J McMurray, Colin J Meyer, Hans-Henrik Parving, Giuseppe Remuzzi, Robert D Toto, Nosratola D Vaziri, Christoph Wanner, Janet Wittes, Danielle Wrolstad, Glenn M ChertowBEACON Trial Investigators

914 Citationer (Scopus)

Abstract

Although inhibitors of the renin-angiotensin-aldosterone system can slow the progression of diabetic kidney disease, the residual risk is high. Whether nuclear 1 factor (erythroid-derived 2)-related factor 2 activators further reduce this risk is unknown.

Originalsprog	Engelsk
Tidsskrift	The New England journal of medicine
Vol/bind	369
Udgave nummer	26
Sider (fra-til)	2492-503
Antal sider	12
ISSN	0028-4793
DOI	https://doi.org/10.1056/NEJMoa1306033
Status	Udgivet - 26 dec. 2013

Adgang til dokumentet

10.1056/NEJMoa1306033

Andre filer og links

Link to publication in Scopus

Citationsformater

de Zeeuw, D., Akizawa, T., Audhya, P., Bakris, G. L., Chin, M., Christ-Schmidt, H., Goldsberry, A., Houser, M., Krauth, M., Lambers Heerspink, H. J., McMurray, J. J., Meyer, C. J., Parving, H.-H., Remuzzi, G., Toto, R. D., Vaziri, N. D., Wanner, C., Wittes, J., Wrolstad, D., ... BEACON Trial Investigators (2013). Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease. The New England journal of medicine, 369(26), 2492-503. https://doi.org/10.1056/NEJMoa1306033

de Zeeuw, D, Akizawa, T, Audhya, P, Bakris, GL, Chin, M, Christ-Schmidt, H, Goldsberry, A, Houser, M, Krauth, M, Lambers Heerspink, HJ, McMurray, JJ, Meyer, CJ, Parving, H-H, Remuzzi, G, Toto, RD, Vaziri, ND, Wanner, C, Wittes, J, Wrolstad, D, Chertow, GM & BEACON Trial Investigators 2013, 'Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease', The New England journal of medicine, bind 369, nr. 26, s. 2492-503. https://doi.org/10.1056/NEJMoa1306033

@article{2e9811cf470f4463a93afa6aecb4ba3f,

title = "Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease",

abstract = "Although inhibitors of the renin-angiotensin-aldosterone system can slow the progression of diabetic kidney disease, the residual risk is high. Whether nuclear 1 factor (erythroid-derived 2)-related factor 2 activators further reduce this risk is unknown.",

author = "\{de Zeeuw\}, Dick and Tadao Akizawa and Paul Audhya and Bakris, \{George L\} and Melanie Chin and Heidi Christ-Schmidt and Angie Goldsberry and Mark Houser and Melissa Krauth and \{Lambers Heerspink\}, \{Hiddo J\} and McMurray, \{John J\} and Meyer, \{Colin J\} and Hans-Henrik Parving and Giuseppe Remuzzi and Toto, \{Robert D\} and Vaziri, \{Nosratola D\} and Christoph Wanner and Janet Wittes and Danielle Wrolstad and Chertow, \{Glenn M\} and \{BEACON Trial Investigators\}",

year = "2013",

month = dec,

day = "26",

doi = "10.1056/NEJMoa1306033",

language = "English",

volume = "369",

pages = "2492--503",

journal = "The New England journal of medicine",

issn = "0028-4793",

publisher = "Massachussetts Medical Society",

number = "26",

}

TY - JOUR

T1 - Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease

AU - de Zeeuw, Dick

AU - Akizawa, Tadao

AU - Audhya, Paul

AU - Bakris, George L

AU - Chin, Melanie

AU - Christ-Schmidt, Heidi

AU - Goldsberry, Angie

AU - Houser, Mark

AU - Krauth, Melissa

AU - Lambers Heerspink, Hiddo J

AU - McMurray, John J

AU - Meyer, Colin J

AU - Parving, Hans-Henrik

AU - Remuzzi, Giuseppe

AU - Toto, Robert D

AU - Vaziri, Nosratola D

AU - Wanner, Christoph

AU - Wittes, Janet

AU - Wrolstad, Danielle

AU - Chertow, Glenn M

AU - BEACON Trial Investigators

PY - 2013/12/26

Y1 - 2013/12/26

N2 - Although inhibitors of the renin-angiotensin-aldosterone system can slow the progression of diabetic kidney disease, the residual risk is high. Whether nuclear 1 factor (erythroid-derived 2)-related factor 2 activators further reduce this risk is unknown.

AB - Although inhibitors of the renin-angiotensin-aldosterone system can slow the progression of diabetic kidney disease, the residual risk is high. Whether nuclear 1 factor (erythroid-derived 2)-related factor 2 activators further reduce this risk is unknown.

UR - https://www.scopus.com/pages/publications/84890946148

U2 - 10.1056/NEJMoa1306033

DO - 10.1056/NEJMoa1306033

M3 - Journal article

C2 - 24206459

SN - 0028-4793

VL - 369

SP - 2492

EP - 2503

JO - The New England journal of medicine

JF - The New England journal of medicine

IS - 26

ER -

Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease

Abstract

Adgang til dokumentet

Andre filer og links

Fingeraftryk

Citationsformater